Ocular Therapeutix™ To Present Data at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
BEDFORD, Mass., April 28, 2023 (GLOBE NEWSWIRE) — Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced multiple scientific presentations at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting being held May 5-8 in San Diego, California.
Related news for (OCUL)
- 24/7 Market News Snapshot 28 May, 2025 – Ocular Therapeutix, Inc. (NASDAQ:OCUL)
- Ocular Therapeutix™ To Close Enrollment This Week for SOL-R, its Second Registrational Trial Evaluating AXPAXLI™ in Wet Age-Related Macular Degeneration
- Ocular Therapeutix™ Reports First Quarter 2025 Results and Business Highlights
- Ocular Therapeutix™ to Report First Quarter 2025 Financial Results on May 5, 2025
- Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2024 Results and Business Highlights